Tyra Biosciences, Inc.
Clinical trials sponsored by Tyra Biosciences, Inc., explained in plain language.
A clinical-stage biotech developing targeted therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test Results expected Sep 2026 (estimated)
- New targeted drug aims to fight hard-to-treat bladder cancers Results expected Nov 2026 (estimated)
-
New pill aims to wipe out rare urinary tract cancer without surgery
Disease control Recruiting nowThis study tests a new drug called dabogratinib in 230 adults with a rare, low-grade cancer in the upper part of the urinary tract. The goal is to see if the drug can make the cancer disappear completely within 6 months. Participants take the drug by mouth and are monitored for s…
Phase 2 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New pill could fight bladder cancer without surgery
Disease control Recruiting nowThis Phase 2 trial tests an oral drug called TYRA-300 in 90 adults with a low-grade, intermediate-risk bladder cancer that has not invaded muscle. The cancer must have a specific genetic change (FGFR3 alteration). Participants take a daily tablet for up to 2 years. The main goal …
Phase 2 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New pill could help kids with dwarfism grow – but early days
Disease control Recruiting nowThis study tests a daily oral drug called TYRA-300 in 92 children aged 3–10 with achondroplasia (a common form of dwarfism). The goal is to see if it safely increases their growth rate. Researchers will try different doses to find the best one. It's a Phase 2 trial, so it's still…
Phase 2 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New pill targets genetic weakness in tough cancers
Disease control Recruiting nowThis early-stage trial tests a new daily pill called TYRA-430 in 100 adults with advanced liver cancer or other solid tumors that have specific genetic changes. The main goals are to find the safest dose and check for side effects. Researchers will also look for signs that the dr…
Phase 1 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC